Advertisement
Advertisement
ZYME
Zymeworks Inc.
29.63
USDSponsored
+0.89
+3.11%
Nov 06, 15:59 UTC -5
Closed
After-Market
29.64
+0.01
+0.02%
Zymeworks Inc. (ZYME) Earnings
ZYME Earnings Reports
Positive Surprise Ratio
ZYME beat 23 of 37 last estimates.
62%
Next Report
Next Week
Date of Next Report
Nov 09, 2026
Estimate for Q3 26 (Revenue/ EPS)
$233.03M
/$2.32
Implied change from Q2 26 (Revenue/ EPS)
+4977.00%
/-474.19%
Implied change from Q3 25 (Revenue/ EPS)
+743.90%
/-992.31%
Zymeworks Inc. earnings per share and revenue
On Aug 06, 2026, ZYME reported earnings of -0.62 USD per share (EPS) for Q2 26, missing the estimate of -0.49 USD, resulting in a -25.13% surprise. Revenue reached 4.59 million, compared to an expected 16.33 million, with a -71.89% difference. The market reacted with a +1.77% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 8 analysts forecast an EPS of 2.32 USD, with revenue projected to reach 233.03 million USD, implying an decrease of -474.19% EPS, and increase of 4977.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Vera Therapeutics, Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$1.65
Actual
-$1.30
Surprise
+21.33%
Moderna, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$1.27
Actual
$0.38
Surprise
+129.79%
Novavax Inc
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.34
Actual
-$0.19
Surprise
+44.56%
Eton Pharmaceutcials, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.31
Actual
$1.06
Surprise
+232.50%
Castle Biosciences, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.13
Surprise
+65.32%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.29
Actual
$0.03
Surprise
+110.09%
PUMA BIOTECHNOLOGY INC
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.09
Actual
$0.15
Surprise
+63.40%
Allogene Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.15
Actual
-$0.15
Surprise
+0.33%
Arcturus Therapeutics Holdings Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.69
Actual
-$0.26
Surprise
+62.44%
Anika Therapeutics Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
$0.06
Actual
$0.28
Surprise
+373.86%
FAQ
What were Zymeworks Inc.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Zymeworks Inc. reported EPS of -$0.62, missing estimates by -25.13%, and revenue of $4.59M, -71.89% below expectations.
How did the market react to Zymeworks Inc.'s Q2 2026 earnings?
The stock price moved up 1.77%, changed from $23.13 before the earnings release to $23.54 the day after.
When is Zymeworks Inc. expected to report next?
The next earning report is scheduled for Nov 09, 2026.
What are the forecasts for Zymeworks Inc.'s next earnings report?
Based on 8
analysts, Zymeworks Inc. is expected to report EPS of $2.32 and revenue of $233.03M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.